The Initial Public Offering (IPO) of Anthem Biosciences has become one of the most talked-about public issues in the Indian equity market. As investor interest grows, the latest data from the grey market suggests that there is strong demand for the company’s shares even before official listing. The company is a key player in the pharmaceutical and biotechnology industry, with a strong track record in contract research and manufacturing services.
Grey Market Premium (GMP) Trends:
As of today, the grey market premium (GMP) for Anthem Biosciences is reported to be in the range of ₹90 to ₹100 per share. This reflects investor confidence and indicates that the stock may list at a premium over the issue price. However, market experts caution that GMP is an unofficial indicator and should not be the sole basis for investment decisions.
IPO Price Band and Lot Size:
Anthem Biosciences has fixed the price band of the IPO between ₹445 and ₹460 per share. The minimum lot size for retail investors is 32 shares, which means an application would require a minimum investment of ₹14,720 at the upper price band. Retail investors can apply for up to 13 lots, depending on availability and regulatory limits.
Important Dates:
- IPO Opening Date: July 22, 2025
- IPO Closing Date: July 24, 2025
- Allotment Date: July 29, 2025
- Refund Initiation: July 30, 2025
- Listing Date: August 1, 2025
Company Overview:
Anthem Biosciences is a Bengaluru-based contract research and manufacturing organization (CRMO) serving pharmaceutical, biotech, and specialty chemical companies globally. It provides services in the areas of drug development, active pharmaceutical ingredient (API) production, and biotechnology research. The company has grown rapidly over the last few years, with a strong client base and expansion plans that are expected to benefit from the IPO proceeds.
The funds raised through the IPO will be used to expand manufacturing capabilities, invest in research infrastructure, repay debts, and meet general corporate expenses. Anthem Biosciences has consistently reported stable revenues and healthy margins, making it an attractive proposition for investors seeking exposure to the healthcare and life sciences sectors.
Expert Views:
Market analysts are positive about the prospects of Anthem Biosciences due to the company's presence in a high-growth sector and its strong operational track record. Many brokerage houses have recommended subscribing to the IPO, especially for investors with a medium- to long-term horizon.
However, as with all equity investments, risks remain. These include regulatory challenges, competitive pressure, and global market volatility. Potential investors are advised to read the red herring prospectus and consult with financial advisors before making any investment decisions.
